Description
CD22 Lentivirus | 78659 | Gentaur US, UK & Europe Disrtribition
Category: Immunotherapy/Lentivirus
Application: Study the transient expression of human CD22 in target cells. Generate a stable cell line expressing human CD22 with limiting dilution and puromycin selection.
Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It acts as an inhibitory co-receptor of the B-cell receptor to control the B-cell immune response. In 2017 the FDA approved Besponsa, an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.
Description: The CD22 Lentiviruses are replication incompetent, HIV based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express human CD22 (NM_001771) under the control of an EF1a promoter.
Product Type: Lentivirus
Shippement Condition: -80°C
